Adverum Biotechnologies to Present at Upcoming Conferences
MENLO PARK, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences:
Investor Presentation: 38th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 15, 2020Time: 2:30 - 2:55 pm PSTLocation: Westin St. Francis Hotel, San Francisco, CAWebcast: A live audio webcast will be accessible under Events and Presentations in the Investors section of the company’s website. The archived audio webcast will be available on the Adverum website following the presentation for 30 days.
Medical Conference Presentation: Macula 20/20 Presentation Title: Results from the OPTIC Trial - Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 in Wet AMDDate: Saturday, January 11, 2020Time: 12:05 pm ESTLocation: New York Academy of Medicine, New York, NYSpeaker: Charles C. Wykoff M.D., Ph.D., director of research, Retina Consultants of Houston; associate professor of clinical ophthalmology, Blanton Eye Institute, Houston Methodist Hospital and Weill Cornell Medical College, Houston Texas
Medical Conference Presentation: Angiogenesis, Exudation, and Degeneration 2020 Presentation Title: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)Date: Saturday, February 8, 2020Time: 2:44 pm ESTLocation: Mandarin Oriental Hotel, Miami, FLSpeaker: David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group; adjunct clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA
About Adverum Biotechnologies, Inc. Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Investors: Myesha Lacy Adverum Biotechnologies Vice President, Investor Relations and Corporate Communications firstname.lastname@example.org 1-650-304-3892
Media: Cherilyn Cecchini, M.D.LifeSci Public Relations Account Supervisor email@example.com 1-646-876-5196